-
Mashup Score: 47Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization - 2 hour(s) ago
Since 1974 substantial gains in childhood survival have occurred in every global region. We estimate that EPI has provided the single greatest contribution to improved infant survival over the past 50 years. In the context of strengthening primary health care, our results show that equitable universal access to immunisation remains crucial to sustain health gains and continue to save future lives from preventable infectious mortality.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1
In the wake of the COVID-19 pandemic, humanity experienced the emergence of another epidemic health threat in 2022. That threat came from human mpox (formerly known as monkeypox) virus—an agent that despite its discovery in 1958, has historically received low attention until recent developments. First reported in humans in 1970, there has since been renewed interest in the disease due to altered transmission and spread mechanisms, and the increased number of cases in 2022.1 WHO declared mpox outbreak a Public Health Emergency of International Concern (PHEIC), following rapid and sustained spread beyond the endemic countries and increases in the number of cases in clusters.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
Dengue fever is a viral infection caused by the dengue virus, which contributes to tens of thousands of deaths annually. Endemic to tropical and subtropical regions, dengue virus is transmitted by Aedes mosquitoes that breed in warm stagnant waters. Upon biting a susceptible host, the virus is transferred to the bloodstream, leading, in most people, to fever and vomiting. At its worst, dengue virus can lead to internal bleeding and death. As an arbovirus (ie, an arthropod-borne virus), the number of dengue-virus infections in an area are often closely linked to mosquito breeding habits, leading to a cyclical pattern of widespread transmission spanning 3–4 years.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
In the wake of the COVID-19 pandemic, humanity experienced the emergence of another epidemic health threat in 2022. That threat came from human mpox (formerly known as monkeypox) virus—an agent that despite its discovery in 1958, has historically received low attention until recent developments. First reported in humans in 1970, there has since been renewed interest in the disease due to altered transmission and spread mechanisms, and the increased number of cases in 2022.1 WHO declared mpox outbreak a Public Health Emergency of International Concern (PHEIC), following rapid and sustained spread beyond the endemic countries and increases in the number of cases in clusters.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 5The Lancet Respiratory Medicine, August 2023, Volume 11, Issue 8, Pages 663-754, e73-e77 - 9 hour(s) ago
Explore the current issue of The Lancet Respiratory Medicine, a monthly journal covering content in respiratory medicine and critical care
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3India's elections: why data and transparency matter - 10 hour(s) ago
Later this month, Indians will head to the polls in what will be the largest election in history. 970 million people, more than 10% of the world population, will vote in the 2024 Lok Sabha (House of the People) parliamentary elections between April 19 and June 4. Opinion polls suggest that Prime Minister Narendra Modi, leader of the Hindu nationalist Bharatiya Janata Party, and his coalition will win a third successive 5-year term. Under Modi’s leadership, India has seen a remarkable, albeit unequal, economic boom.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Dengue fever is a viral infection caused by the dengue virus, which contributes to tens of thousands of deaths annually. Endemic to tropical and subtropical regions, dengue virus is transmitted by Aedes mosquitoes that breed in warm stagnant waters. Upon biting a susceptible host, the virus is transferred to the bloodstream, leading, in most people, to fever and vomiting. At its worst, dengue virus can lead to internal bleeding and death. As an arbovirus (ie, an arthropod-borne virus), the number of dengue-virus infections in an area are often closely linked to mosquito breeding habits, leading to a cyclical pattern of widespread transmission spanning 3–4 years.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 23Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial - 12 hour(s) ago
Cabozantinib shows promising activity in patients with MPPGs.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE - 13 hour(s) ago
Launched as a public–private partnership funded by the Foundation for the National Institutes of Health, the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE) aims to change the framework for how clinical trials of new anti-osteoporosis drugs are conducted, to promote innovation in the field of osteoporosis, where underdiagnosis and undertreatment of disease have been deemed a crisis.1 Osteoporosis-related fractures, which lead to high morbidity and increased mortality, are a large and growing public health concern as one in two women and one in five men over the age of 50 years will have a fracture.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 12
Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer. Future randomised controlled trials of nivolumab plus ipilimumab or other dual immunotherapy regimens are warranted to confirm treatment benefit in this patient population.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
That's striking https://t.co/J8MnYOoBC3 New @TheLancet Benefits for infants and children at 50-year anniversary of a global health program https://t.co/KyFu06HZTI